The review discusses fifty eight peptides in numerous clinical phases, indicating a robust pipeline of peptide therapies concentrating on PPIs. Any potential conflicts of curiosity, for example funding from pharmaceutical corporations or own investments in relevant industries, are completely disclosed from the research publications. This disclos